{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 73,
        "end": 97
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 100,
        "end": 103
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 138,
        "end": 145
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 188,
        "end": 203
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 260,
        "end": 271
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 287,
        "end": 296
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22974536_2",
  "text": "BACKGROUND : A recent clinical trial has demonstrated that patients with acute coronary syndromes ( ACS ) and the reduced function allele CYP2C19 * 2 ( * 2 allele ) , who are treated with thienopyridines , have an increased risk of adverse cardiac events with clopidogrel , but not with prasugrel ."
}
